DXCOVER is a multi-omic clinical stage liquid biopsy company developing tests for the early detection of multiple solid tumor cancers and other diseases, when treatment has a better chance to impact outcomes.
The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers, leveraging artificial-intelligence to achieve same-day detection of cancer from a simple blood sample, enabling rapid diagnosis and stratification of patients for earlier treatment to improve survival and quality of life.
The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. DXCOVER is based in Glasgow, Scotland, United Kingdom and is establishing operations in the US (Nashville TN.)